Clinical News

Alecensa a New First-Line Treatment for NSCLC with ALK Mutation

December 2017, Vol 7, No 12 - FDA News

On November 6, 2017, the FDA approved alectinib (Alecensa; Genentech) for the treatment of patients with ALK mutation–positive, metastatic non–small-cell lung cancer (NSCLC), as detected by an FDA-approved test. On the same day, the FDA also converted alectinib’s initial accelerated approval to a full approval for the treatment of patients with metastatic NSCLC and ALK mutation whose disease progressed with or who were intolerant of crizotinib (Xalkori). [ Read More ]

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

October 2017, Vol 7, No 10 - FDA News, Leukemia

On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa; Pfi­zer), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22. The FDA designated inotuzumab ozogamicin as an orphan drug and applied its priority review for this approval. [ Read More ]

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh

September 2017, Vol 7, No 9 - Breast Cancer, Drug Update

Breast cancer is one of the most common cancer diagnoses in the United States. The National Cancer Institute estimates that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from the disease in 2017. For the majority (62%) of women with breast cancer, the disease is confined to the breast, and the 5-year survival approaches 100%. However, for women with metastatic disease, the likelihood of survival at 5 years drops to 27%. [ Read More ]

FDA News – September 2017

September 2017, Vol 7, No 9 - FDA News

  • Enasidenib, a New Targeted Therapy Approved for Relapsed or Refractory AML
  • Ibrutinib First Treatment Approved by the FDA for Chronic Graft-versus-Host Disease
  • Vyxeos First Treatment Approved Specifically for 2 Types of High-Risk AML
  • First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell Acute Lymphoblastic Leukemia in Young Patients
[ Read More ]

Managing Self-Pay Accounts Receivable in Oncology

Matt Terry, MBA, BSRT

September 2017, Vol 7, No 9 - Billing/Accounts Receivable

Self-pay accounts receivable in healthcare includes true self-pay (ie, patients with no health insurance) and the patient responsibility after insurance. In the past, health insurance plan benefits covered much more of the patient’s bill, up to 90% or more; however, in the past few years, high-deductible health plans have become more common and more attractive for plan members because of lower monthly premiums. Thus, the patient responsibility after insurance has shifted from 10% of the collectible accounts receivable to upwards of 30%. [ Read More ]

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma

Lisa A. Raedler, PhD, RPh

August 2017, Vol 7, No 8 - Drug Update

Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. MZL is divided into 3 subtypes, including mucosa-associated lymphoid tissue (MALT), nodal MZL, and splenic MZL. [ Read More ]